San Francisco, CA, United States of America

Martha Jo Whitehouse

This inventor holds 17 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Cardiovascular Treatments. Top assignees: Novartis Vaccines & Diagnostics, Gmbh, Corthera Inc., Chiron Corporation. Active years: 2002-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martha Jo Whitehouse. Retrieved from https://idiyas.com/inventor/martha-jo-whitehouse

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 7)

% Patents Active = 17.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 1.8

ph-index = 5

Forward Citations = 93(Granted Patents)

Location History:

San Mateo, CA (US) (2013)
San Francisco, CA (US) (2002 - 2017)

Company Filing History:

7 out of 245

Novartis Vaccines & Diagnostics, Gmbh

Years Active: 2002-2017

Loading Chart...

Areas of Expertise:

Coronary Artery Disease

FGF-2

Heart Failure

Peripheral Artery Disease

Neurohormonal Imbalance

FGF-9

Dyspnea Treatment

Angiogenic Therapy

FGF-4

FGF-5

Mortality Reduction

FGF Administration

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9579363 - Method of lowering mortality (2017-02-28),

2. 9205132 - Method of lowering mortality (2015-12-08),

3. 9149507 - Method of treating coronary artery disease by administering FGF-9 (2015-10-06),

4. 9066916 - Method of treating neurohormonal imbalance (2015-06-30),

5. 8796211 - Method of treating coronary artery disease FGF-2 (2014-08-05),

6. 8618052 - Method of treating coronary artery disease by administering FGF-5 (2013-12-31),

7. 8415301 - Method of treating dyspnea associated with acute heart failure by administering H2 relaxin (2013-04-09),

8. 8372809 - Method of treating dyspnea associated with acute heart failure (2013-02-12),

9. 8053411 - Method of treating dyspnea associated with acute heart failure (2011-11-08),

10. 7858584 - Angiogenically effective unit dose of FGF and method of administering (2010-12-28),

11. 7541337 - Methods and compositions for the treatment of peripheral artery disease (2009-06-02),

12. 7541333 - Angiogenically effective unit dose of FGF-2 and method of use (2009-06-02),

13. 7511019 - Method of treating coronary artery disease by administering FGF-4 (2009-03-31),

14. 7186407 - Methods and compositions for the treatment of peripheral artery disease (2007-03-06),

15. 7112560 - Angiogenically effective unit dose of FGF-2 and method of use (2006-09-26),

Title: Martha Jo Whitehouse: Innovator in Cardiac Health

Introduction

Martha Jo Whitehouse is a prominent inventor based in San Francisco, CA, known for her significant contributions to cardiac health. With a total of 17 patents to her name, she has made remarkable strides in the field of medicine, particularly in treating acute heart conditions.

Latest Patents

Among her latest patents is a method aimed at lowering mortality rates in patients suffering from acute decompensated heart failure. This innovative approach involves administering a pharmaceutically effective amount of relaxin to treat acute cardiac decompensation. Her work focuses on reducing decompensation through acute intervention, showcasing her commitment to improving patient outcomes.

Career Highlights

Martha has worked with notable companies such as Novartis Vaccines & Diagnostics and Corthera Inc. Her experience in these organizations has allowed her to develop and refine her groundbreaking methods in cardiac care.

Collaborations

Martha has collaborated with esteemed colleagues, including Elaine Unemori and Sam L Teichman, further enhancing her research and development efforts in the medical field.

Conclusion

Martha Jo Whitehouse's innovative work in cardiac health exemplifies her dedication to improving patient care through her patented methods. Her contributions continue to influence the medical community and offer hope for better treatment options in the future.

Profile summary based on public USPTO records.